Provided by Tiger Fintech (Singapore) Pte. Ltd.

Monopar Therapeutics

39.10
+4.7313.76%
Post-market: 39.100.00000.00%19:23 EDT
Volume:46.16K
Turnover:1.73M
Market Cap:238.45M
PE:-19.91
High:42.96
Open:36.56
Low:34.50
Close:34.37
Loading ...

Company Profile

Company Name:
Monopar Therapeutics
Exchange:
NASDAQ
Establishment Date:
2014
Employees:
10
Office Location:
1000 Skokie Boulevard,Suite 350,Wilmette,Illinois,United States
Zip Code:
60091
Fax:
- -
Introduction:
Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. Its lead product candidate in development is Validive, a clonidine hydrochloride mucobuccal tablet that is in Phase 2b/3 clinical trial for the prevention of chemoradiotherapy induced severe oral mucositis in patients with oropharyngeal cancer. The company also engages in developing Camsirubicin, an analog of doxorubicin, which is in Phase 1b clinical trial for the treatment of advanced soft tissue sarcoma; MNPR-101, a urokinase plasminogen activator receptor targeted antibody for the treatment of various cancers; MNPR-101 RIT, a radioimmunotherapeutic based on MNPR-101 for the potential treatment of cancer and severe COVID-19; and MNPR-202, an analog of camsirubicin to treat doxorubicin-and camsirubicin-resistant cancers. Monopar Therapeutics Inc. has collaborations with the Grupo Español de Investigación en Sarcomas for the development of camsirubicin in patients with advanced soft tissue sarcoma; NorthStar Medical Radioisotopes, LLC to develop radio-immuno-therapeutics targeting severe COVID-19; and the Cancer Science Institute of Singapore to evaluate the activity of MNPR-202 and related analogs in various types of cancer. The company was founded in 2014 and is headquartered in Wilmette, Illinois.

Directors

Name
Position
Chandler D. Robinson
Chief Executive Officer, Director
Christopher M. Starr
Executive Chairman, Director
Andrew P. Mazar
Executive Vice President of Research and Development, Chief Scientific Officer, Director
Arthur J. Klausner
Director
Michael J. Brown
Director
Raymond W. Anderson
Director

Shareholders

Name
Position
Chandler D. Robinson
Chief Executive Officer, Director
Kim R. Tsuchimoto
Chief Financial Officer, Secretary and Treasurer
Andrew P. Mazar
Executive Vice President of Research and Development, Chief Scientific Officer, Director
Christopher M. Starr
Executive Chairman, Director
Patrice Rioux
Acting Chief Medical Officer